Study to Learn About How the Study Medicines Called PF-07976016 and PF-06882961 Are Taken Up by the Body, and if Either of Them Change How the Body Processes the Other Medicine in Otherwise Healthy Adults With Overweight or Obesity

Pfizer

Status and phase

Active, not recruiting

Phase 1

Conditions

Overweight

Obesity

Treatments

Drug: PF-06882961

Drug: PF-07976016

Study type

Interventional

Funder types

Industry

Identifiers

NCT06910839

C5541009

Details and patient eligibility

About

The purpose of this study is to see how two study medicines, PF-07976016 and danuglipron, taken together affect the level of each other in the blood of participants who have overweight or obesity.

The total number of weeks of the study is up to approximately 22 weeks (5.5 months).

Enrollment

21 patients

Sex

All

Ages

18 to 65 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Male and non-pregnant, non-breastfeeding female, 18 to 65 years of age
BMI 25 to 40 kg/m2 and a total body weight > 50 kg (110 lb)
Willing and able to comply with all study procedures including staying a research unit for up to 95 days

Exclusion criteria

Any medical or psychiatric condition or laboratory abnormality, or recent serious illness or hospitalization, that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study including diagnosis of type 2 diabetes mellitus, type 1 or secondary forms of diabetes
Use of any prohibited prior or concomitant medication(s)
Presence of specified abnormalities on diagnostic assessments including clinical laboratory tests
A positive urine drug test.
History of alcohol abuse or repeated binge drinking and/or any other illicit drug use or dependence
Use of tobacco/nicotine containing products in excess of the equivalent of 5 cigarettes/day or 2 chews of tobacco/day